NIDR and NCI Establish Four Research Centers for Oral Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 11
Volume 5
Issue 11

BETHESDA, Md-With the aim of increasing oral cancer survival rates, the National Institute of Dental Research (NIDR) and the National Cancer Institute will jointly fund four research centers to investigate the causes of oral cancers and to develop improved treatments.

BETHESDA, Md—With the aim of increasing oral cancer survival rates, the National Institute of Dental Research (NIDR) and the National Cancer Institute will jointly fund four research centers to investigate the causes of oral cancers and to develop improved treatments.

The four centers will receive a total of $2.8 million during fiscal 1997 and additional funds in the following 4 years. They will be located at the University of Alabama at Birmingham; the University of California, San Francisco; the University of Chicago and Northwestern University; and the University of Texas M.D. Anderson Cancer Center.

Recent Videos
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content